期刊文献+

LRIG1在脑胶质瘤中的研究进展 被引量:1

Recent advance in role of leucine-rich repeats and immunoglobulin- like domains 1 in gliomas
原文传递
导出
摘要 在寻找哺乳动物表皮生长因子受体(epidermalgrowthfactorreceptor,EGFR)负调控蛋白的过程中,与果蝇Kek1蛋白(EGFR负反馈因子1结构相似的多亮氨酸重复区免疫球蛋白样蛋白1(leucine-rich repeats and immunoglobulin- likedomains 1, LRIG1)步入了研究者的视野。2001年,Nilsson等从人脑中成功克隆了LRIGJ基因。
出处 《中华神经医学杂志》 CAS CSCD 北大核心 2015年第10期1074-1077,共4页 Chinese Journal of Neuromedicine
关键词 LRIG1 神经胶质瘤 治疗 LRIG1 Glioma Treatment
  • 相关文献

参考文献35

  • 1Musacchio M, Perrimon N, The Drosophila kekkon genes: novel members of both the leucine-rich repeat and immunoglobulin superfamilies expressed in the CNS[J]. Dev Biol, 1996, 178(1): 63 -76.
  • 2Nilsson J, Vallbo C, Guo D, et al. Cloning, characterization, and expression of human LIG1 [J]. Biochem Biophys Res Commun, 2001, 284(5): 1155-1161.
  • 3Gur G, Rubin C, Katz M, et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation [J]. EMBO J, 2004, 23(16): 3270-3281.
  • 4Laederich MB, Funes-Duran M, Yen L, et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases [J]. J Biol Chem, 2004, 279 (45): 47050-47056.
  • 5Hedman HK, Nilsson J, GuoD, et al. Is LRIG1 a tumour suppressor gene at chromosome 3p14.3 [J]. Acta Oncologica, 2002, 41 (4): 352-354.
  • 6Powell AE, Wang Y, Li Y, et al. The pan-ErbB negative regulator Lrigl is an intestinal stem cell marker that functions as a tumor suppressor[J]. Cell, 2012, 149(1): 146-158.
  • 7Wong VW, Stange DE, Page ME, et al. Lrigl controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling[J]. Nat Cell Biol, 2012, 14(4): 401-408.
  • 8Stutz M.A, Shattuck DL, Laederich MB, et al. LRIG1 negativelyregulates the oncogenic EGF receptor mutant EGFRvlII [J]. Oncogene, 2008, 27(43): 5741-5752.
  • 9Shattuck DL, Miller JK, Laederich M, et al. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy[J]. Mol Cell Biol, 2007, 27(5): 1934-1946.
  • 10Ledda F, Bieraugel O, Fard SS, et al. Lrigl is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF[J]. J Neurosci, 2008, 28(1): 39-49.

二级参考文献6

共引文献3

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部